

August 9, 2024

Brain Tumour Foundation of Canada has learned that on August 6th, 2024, the United States Food and Drug Administration (FDA) approved vorasidenib for grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.

We are hopeful that this approval in the US will lead Canada one step closer to a new treatment option for brain tumour patients.

For more information about the FDA approval, please [click here](#).

If you have any questions or concerns about this issue or Brain Tumour Foundation of Canada's advocacy efforts, please contact:

Sarah Rogers
Advocacy and Information Specialist
srogers@braintumour.ca